Curative intent of local excision alone for stage I anal canal squamous cell carcinoma (ACSCC).

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e15574-e15574
Author(s):  
Zhaohui Jin ◽  
Sakti Chakrabarti ◽  
Brandon M Huffman ◽  
Christopher Leigh Hallemeier ◽  
Joleen Marie Hubbard ◽  
...  
2019 ◽  
Vol 10 (2) ◽  
pp. 171-178 ◽  
Author(s):  
Sakti Chakrabarti ◽  
Zhaohui Jin ◽  
Brandon M. Huffman ◽  
Siddhartha Yadav ◽  
Rondell P. Graham ◽  
...  

2019 ◽  
Vol 26 (4) ◽  
pp. 1025-1028
Author(s):  
Jaren Lerner ◽  
Miguel Michel ◽  
Constantin A Dasanu

Introduction Conventional first-line therapy for squamous cell carcinoma of anal canal is definitive chemoradiotherapy with a curative intent. Due to the efficacy of treatment for locoregional disease and rarity of metastatic anal carcinoma, clinical trial data for treatment of metastatic disease is lacking. Case report Herein, we describe a patient with relapsed, metastatic squamous cell carcinoma of the anal canal treated with cetuximab as the third-line therapy. Management and outcome: The patient responded to this pharmacological agent, meeting the definition of a partial response per response evaluation criteria in solid tumors (RECIST). Discussion EGFR inhibitors are potential avenues for the subsequent lines of therapy in metastatic or relapsed/refractory anal cancer. Prospective clinical trials of cetuximab alone or in combination with other agents are warranted in this setting in the future.


2020 ◽  
Vol 31 ◽  
pp. S458
Author(s):  
I.K.F. Lustosa ◽  
M.P.G. Camandaroba ◽  
B.R.S. Mattos ◽  
S.F. Silva ◽  
S. Iseas ◽  
...  

2016 ◽  
Vol 34 (4_suppl) ◽  
pp. 573-573 ◽  
Author(s):  
Cathy Eng ◽  
Richard A. Adams ◽  
Lisa A. Kachnic ◽  
Prajnan Das ◽  
Randy Devereux Ernst ◽  
...  

573 Background: Squamous cell carcinoma of the anal canal will be diagnosed in 28,000 individuals globally. Considered a rare cancer, the incidence of anal carcinoma continues to rise annually. Majority of patients present with locally advanced disease in which concurrent chemoradiation (CRT) will be provided with curative intent. The Anal Cancer IRCI Working Group was created to pursue novel approaches to the diagnosis, treatment, and surveillance of patients. Yet, surveillance following completion of CRT is not well established and varies as per NCCN (v2.2015) and ESMO guidelines. Methods: A 22-question survey provided to anonymous international GI subspecialists in various fields. Questions pertained to timing and type of diagnostic imaging, surveillance interval, approach to detection of complete response (CR), and prevention of sexual dysfunction. Results: Survey distribution was initiated in March 2015 and still ongoing. Thus far, 96 physicians responded. Conclusions: Carcinoma of the anal canal continues to rise in incidence annually. Surveillance following completion of CRT is warranted; however, global variability in practice patterns for surveillance exists. As such, the IRCI Anal Cancer Working Group intends to provide an international consensus surveillance statement. [Table: see text]


2020 ◽  
Vol 46 (9) ◽  
pp. 1663-1667 ◽  
Author(s):  
Xiang Gao ◽  
Paolo Goffredo ◽  
Amanda R. Kahl ◽  
Mary E. Charlton ◽  
Ronald J. Weigel ◽  
...  

Cancers ◽  
2020 ◽  
Vol 12 (11) ◽  
pp. 3248
Author(s):  
Eric Miller ◽  
Ansel Nalin ◽  
Dayssy Diaz Pardo ◽  
Andrea Arnett ◽  
Laith Abushahin ◽  
...  

The optimal treatment for stage I squamous cell carcinoma of the anus (SCCA) remains undefined. Recently, wide local excision alone was found to have comparable survival to those treated with chemoradiation (CRT). Given that local excision may be sufficient for the treatment of stage I SCCA, we hypothesized that radiation therapy (RT) alone, compared to CRT would result in equivalent overall survival (OS) in this population. We identified non-surgically treated patients with stage I SCCA from the National Cancer Database from 2004–2015. We included only patients treated either with CRT (45–59.4 Gy with chemotherapy initiated within 14 days of RT) or RT alone (45–59.4 Gy with no chemotherapy). The primary endpoint was OS between CRT and RT patients. Propensity-score matched (PSM) analysis was performed to determine the effect of concurrent chemotherapy on OS using a Cox proportional hazards model with robust standard error to account for clustering in matched pairs. We identified 3552 stage I patients treated with CRT and 287 treated with RT. Compared to patients treated with CRT, those that received RT were more likely to be ≥70 years old (33.1% vs. 19.7%, p < 0.001) and less likely to be female (63.1% vs. 71.0%, p < 0.001). The proportion of patients with a Charlson-Deyo score of 0 was similar in both groups (80.8% RT vs. 82.7% CRT, p = 0.164). The PSM cohort consisted of 287 pairs of patients with median follow-up 48.3 months (interquartile range, 24.4–85.1 months) and 151 deaths (86 RT, 65 CRT). CRT was associated with a 31% reduction in the risk of death (HR = 0.69, 95% CI 0.50–0.95, p = 0.023). We found that CRT was associated with improved OS, compared to RT alone, in patients with non-surgically treated stage I SCCA. These data suggest that de-intensification of therapy in stage I SCCA must be used with caution. However, given the retrospective nature of the data, prospective trials are required.


JAMA Surgery ◽  
2018 ◽  
Vol 153 (3) ◽  
pp. 209 ◽  
Author(s):  
Christy Y. Chai ◽  
Hop S. Tran Cao ◽  
Samir Awad ◽  
Nader N. Massarweh

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 4060-4060 ◽  
Author(s):  
Cathy Eng ◽  
Jane Rogers ◽  
George J. Chang ◽  
Y. Nancy You ◽  
Prajnan Das ◽  
...  

4060 Background: Metastatic squamous cell carcinoma (SCCA) of the anal canal is an uncommon malignancy with no standard approach. The reported median overall survival (OS) is 9-12 months (M) following 5-FU + cisplatin (FC)-based therapy. The aim of this study is to evaluate first-line chemotherapy approaches in this patient (pt) population. Methods: A retrospective analysis was conducted of 428 pts with metastatic SCCA of the anal canal identified from the MDACC tumor registry between 1/1/2000 - 5/31/2011. Electronic medical records were reviewed for histology, date of diagnosis and/or recurrence, site of metastasis, type of therapy provided, response rate (RR), progression-free survival (PFS), OS, and lines of salvage therapy. All eligible pts were required to be treatment-naïve for metastatic disease and have radiographic imaging at MDACC. Waiver of informed consent was obtained. Results: 99 pts fulfilled all criteria; 10 were lost to follow-up; 12 did not initiate chemotherapy. 77 pts were evaluable; M: F = 20:57; median age = 55 years (range: 37 - 82); HIV(+) = 5% (4/77); prior chemoXRT with curative intent: 70% (54/77), complete response (CR): 87% (47/54), median time to development of metastatic disease =17M. 29% (22/77) presented with metastatic disease. Sites of disease included distant lymph nodes (41%); liver (45 %); lung (25%); bone (15%); and brain (8%). The median follow up was 37M. 73% (56/77) of patients were treated with platinum-based therapy; 51% (n=39) received FC and 22% (n= 17) received carboplatin + paclitaxel (CP). The median PFS was 6M; FC trended better than CP for PFS (7M vs. 5M, p<0.067). The overall median OS = 29M. 40% (31/77) of pts received neoadjuvant first-line therapy followed by metastasectomy (68%), XRT (26%), or both (6%); resulting in a median OS = 35M. Conclusions: Metastatic SCCA of the anal canal is a malignancy in which 5-FU+cisplatin is a commonly used regimen. Our analysis suggests FC results in improved PFS over CP but is underpowered supporting further analysis. The short median PFS with front-line chemotherapy, and yet longer OS reflects the challenges in treating this patient population and the importance of multidisciplinary management in select cases.


2021 ◽  
Vol 32 ◽  
pp. S538
Author(s):  
R.P. Riechelmann ◽  
M. Camandaroba ◽  
C.A. Mello ◽  
S. Aguiar

Sign in / Sign up

Export Citation Format

Share Document